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Objective: Extracardiac and lateral tunnel total cavopulmonary connection are
currently 2 major options for patients with a single ventricle physiology. However,
each procedure has some disadvantages over the other. We developed a new
technique of extracardiac total cavopulmonary connection using a tissue-engineered
graft to overcome some of the disadvantages previously associated with both the
extracardiac and lateral tunnel procedures.
Methods: Between February 2001 and October 2002, 8 patients underwent an
extracardiac total cavopulmonary connection using a tissue-engineered graft in our
institution. Collected bone marrow cells (1  108 mononucleocytes) from a patient
(1-4 mL/kg body weight) were seeded onto a biodegradable scaffold composed of
polycaprolactone-polylactic acid copolymer reinforced with woven polylactic acid.
After a 2- to 4-hour cultivation, the seeded scaffold was implanted as an extracardiac
conduit during the total cavopulmonary connection operation.
Results: There were no hospital or late deaths. At a mean follow-up of 13.4 months
(range 4-25 months), all patients are alive and asymptomatic with no need for repeat
surgery. A postoperative catheter examination or computed tomography showed all
tissue-engineered grafts to be patent and revealed no stenosis, obstruction, or
aneurysmal change in the 8 patients.
Conclusion: We believe that extracardiac total cavopulmonary connection using a
tissue-engineered graft has the potential to overcome some of the disadvantages
previously associated with extracardiac or lateral tunnel total cavopulmonary con-
nection. However, an extended follow-up period is required to clarify the long-term
clinical outcome for the tissue-engineered graft.
Since de Leval and his colleagues introduced the total cavopulmonaryconnection (TCPC) procedure in 1988, it has been widely performedas a modification of the Fontan operation in patients with a singleventricle physiology.1 Two major TCPC options are the extracardiac(inferior vena cava [IVC]-right pulmonary artery [PA] conduit) andthe lateral tunnel (intra-atrial) procedures.2 Outcomes after the Fontan
operation have improved markedly in the past 15 years with the use of these 2
procedures.3-7
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Each of these procedures, however, has some advantages
and disadvantages over the other. Extracardiac TCPC has a
lower frequency of late supraventricular arrhythmias in
comparison with lateral tunnel TCPC,6,7 because no part of
the right atrium is exposed to an elevated systemic venous
pressure, and because there are no extensive atrial suture
lines. In addition, extracardiac TCPC is a technically unde-
manding procedure when compared with lateral tunnel
TCPC in avoiding pulmonary venous obstruction because of
the interference of the systemic venous route. On the other
hand, extracardiac TCPC requires a prosthetic conduit to
connect the IVC to the right PA. However, foreign material
(usually polytetrafluoroethylene) has no growth potential.
This situation may necessitate a later conduit replacement
and increase the risk of conduit thrombosis,8,9 although the
lateral tunnel could be completed without the use of foreign
material.
We applied a tissue-engineered graft (TEG) during an
extracardiac TCPC operation to overcome some of the
disadvantages that were associated previously with both the
extracardiac and lateral tunnel TCPC procedures.
Material and Methods
After having received approval from the ethics committee at
Tokyo Women’s Medical University, we began the clinical appli-
cation of TEG. Informed consent was obtained directly from the
21-year-old patient and from the parents of the younger patients.
Between February 2001 and October 2002, 8 patients underwent
an extracardiac TCPC using a TEG in our institution (Table 1).
The mean age at operation was 8.5 years (range 1-21 years), and
the mean weight was 22.5 kg (range 9.2-44 kg). The primary
diagnosis was asplenia in 3 patients, polysplenia in 2 patients
(azygos continuation of the IVC in 1), and normotaxia in 3
patients. The concomitant procedures were as follows: angioplasty
of the PA in 3 patients, redo-plasty of the common atrioventricular
TABLE 1. Summary of clinical data for 8 patients undergoing extracardiac total cavopulmonary connection
Patient No. Heterotaxia Diagnosis
Age at TCPC
(yr) Prior procedures
1 Polysplenia AV septal defect 12 Extracardiac TCPC using Hemashield (Boston
Scientific Corp, Natick Mass) graft
2 Asplenia AV septal defect, PAPVD 2 Bilateral MBTs
3 Asplenia Single RV, TAPVD, pulmonary stenosis 1 Left MBT
4 None Concordant crisscross heart 7 Left MBT
DORV, pulmonary atresia Atrial septectomy
5 None Tricuspid atresia, pulmonary stenosis 21 Bilateral OBTs central shunt
6 None Single RV, left AV valve atresia 4 Bidirectional Glenn
7 Asplenia Single LV, CAVV regurgitation 17 Bidirectional Glenn CAVV plasty
8 Polysplenia Single RV, CAVV regurgitation,
hemiazygos connection
4 TCPS CAVV plasty
TEG diameter
(mm) Concomitant procedures
CPB time
(min)
ACC time
(min)
Hospital stay
(d)
20 Removal of previous Hemashield graft 127 0 139
17 PA angioplasty PAPVD repair 186 0 70
20 TAPVD repair 170 0 46
18 PA angioplasty 105 0 40
24 None 169 0 47
20 PA angioplasty 105 0 30
24 Redo-CAVV plasty 144 110 44
12 Redo-CAVV plasty 93 37 29
Complications Follow-up period (mo) Heart rhythm
Pleural effusion 25.6 Sinus
Pleural effusion 18.0 Sinus
None 16.6 Sinus
None 13.7 Sinus
None 11.6 Sinus
None 9.4 Sinus
None 8.4 Sinus
None 4.4 Pacing
ACC, Aortic crossclamp; AV, atrioventricular; CAVV, common atrioventricular valve; CPB, cardiopulmonary bypass; DORV, double-outlet right ventricle; LV,
left ventricle; MBT, modified Blalock-Taussig shunt; OBT, original Blalock-Taussig shunt; PA, pulmonary artery; PAPVD, partial anomalous pulmonary
venous drainage; PS, pulmonary stenosis; RV, right ventricle; TCPC, total cavopulmonary connection; TCPS, total cavopulmonary shunt; TEG, tissue-
engineered graft; TAPVD, total anomalous pulmonary venous drainage.
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valve in 2 patients, repair of total anomalous pulmonary venous
drainage in 1 patient, and repair of partial anomalous pulmonary
venous drainage in 1 patient. One patient (patient 8) required DDD
pacemaker placement simultaneously because of atrial bigeminy
that had been present preoperatively.
The procedures for cell harvesting and cell seeding have been
described.10 Briefly, before a median sternotomy, autologous bone
marrow cells (BMCs), approximately 1 to 4 mL/kg body weight,
were collected from the anterior superior iliac spine in the oper-
ating room. Aspirated BMCs (1  108 mononucleocytes) were
seeded onto a biodegradable scaffold composed of polycaprolac-
tone-polylactic acid copolymer reinforced with woven polylactic
acid. This scaffold was designed to degrade by hydrolysis in
approximately 3 to 5 years. The seeded scaffold was kept in a
culture medium until TCPC anastomosis for approximately 2 to 4
hours at 37°C in 100% humidity and a 5% CO2 atmosphere.
The operation was performed by conventional cardiopulmo-
nary bypass with ascending aortic perfusion and direct bicaval (or
tricaval, when necessary) venous drainage. Previous systemic to
pulmonary shunts, if present, were taken down immediately after
bypass onset. TCPC anastomosis using a TEG was performed
under total bypass with a beating heart in all patients except for 2
in whom atrioventricular valve plasty was required. The superior
vena cava was anastomosed to the upper surface of the right PA in
an end-to-side fashion. The IVC was clamped and transected at the
inferior cavoatrial junction. A TEG selected according to the
orifice size of the IVC was sutured to the IVC in an end-to-end
manner. The caudal aspect of the central PA was opened widely,
after which the other end of the TEG was sutured to the PA with
a conduit offset a few millimeters toward the proximal PA (Figure
1). Anastomosis between the TEG and the native tissue was
performed using absorbable PDS running suture (Ethicon Inc,
Summerville, NJ), except in patients 5 (21 years old) and 7 (17
years old). Anticoagulation therapy with warfarin sodium and
aspirin was continued until 6 months after operation. Thereafter,
anticoagulation therapy with aspirin alone was continued for 12
months postoperatively.
Results
The diameter of the TEG was 17 mm in 1 patient, 18 mm in
1 patient, 20 mm in 3 patients, 24 mm in 2 patients, and 12
mm in 1 patient with azygos continuation (Table 1). The
mean cardiopulmonary bypass time was 137  35 minutes.
No patients required fenestration in this series.
There were no hospital deaths, and the mean hospital
stay was 55.6 days (range 29-127 days). At a mean fol-
low-up of 13.4 months (range 4-25 months), all patients are
alive and asymptomatic with no need for repeat surgery. A
postoperative catheter examination (in 4 patients), com-
puted tomography (in 2 patients), or magnetic resonance
imaging (in 2 patients) showed all TEGs to be patent and
revealed no stenosis, obstruction, thrombotic complications,
or aneurysmal change in any of the 8 patients (Figure 2).
Sinus rhythm was maintained in 7 patients, and pacing
rhythm was observed in 1 patient who required DDD pace-
maker (Medtronic, Inc, Shoreview, Minn) implantation. No
atrial dysrhythmias were identified by a routine electrocar-
diographic examination at our outpatient unit.
Discussion
One of the important features of our technique is that the
scaffold used here is designed to disappear in 3 to 5 years
after the TCPC operation. Thus, the whole structure of the
conduit connecting the IVC to the PA should be replaced by
autologous tissue, and the permanent presence of foreign
material can be avoided. In light of these characteristics, the
theoretic advantages of the TEG that we used here are its
growth potential, low degree of thrombogenicity and calci-
fication, and great resistance to infection. The age of pa-
tients undergoing the TCPC operation is currently trending
much younger because of the consensus that cyanosis
should be corrected in the early years. The younger the
patients with TCPC are, the greater will be their somatic
growth, making the benefits of the TEG significant.
Azygos or hemiazygos continuation is a difficult situa-
tion in TCPC surgery for patients with heterotaxia syn-
drome. Because blood flow from the hepatic vein is lower
than that of the normal IVC, the risk of conduit thrombosis
may be higher.9 A TEG, even in this situation, would have
better long-term patency than polytetrafluoroethylene be-
cause a TEG has the potential for remodeling into appro-
priate dimensions according to blood flow through the con-
duit.
For the first patient in this series, cells were isolated from
the saphenous vein wall and cultured to make the TEG as
we previously reported.11-13 However, general anesthesia
was mandatory to isolate the cells in children, and a 3-week
cell culture was required to construct the TEG. As a result,
we used autologous BMCs as a cell source in all other
patients, because they contained multipotential cells capable
of differentiating into several different tissue types.14-16 In
Figure 1. Operative field. IVC, Inferior vena cava; PA, pulmonary
artery; TEG, tissue-engineered graft placed between the IVC and
the right PA.
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addition, the collection of BMCs could be performed on the
same day as the operation, which thus rendered it unneces-
sary for hospital admission before the TCPC operation.
Anticoagulation therapy after the extracardiac TCPC op-
eration remains controversial. From our experimental data
on dogs, endothelialization of the inner surface of the TEG
was observed at 1 to 3 months after TEG implantation.12
Therefore, patients who had a TEG implanted in this series
received anticoagulation therapy with both warfarin sodium
and aspirin for 6 months after surgery and with aspirin alone
for 6 months thereafter.
Conclusion
We believe that extracardiac TCPC with a TEG has the
potential to overcome the disadvantages associated with
previous extracardiac or lateral tunnel TCPC. However, an
extended follow-up period is still required to clarify the
long-term clinical outcome for TEGs.
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